DIAGNOSTICS AND TREATMENT: Funding to further bio-optics products

Sept. 1, 2008
Three start-up companies developing medical devices have raised new funding to support product development and commercialization.

Three start-up companies developing medical devices have raised new funding to support product development and commercialization.

Electro-Optical Sciences, Inc.

Electro-Optical Sciences (Irvington, NY), developer of MelaFind, a noninvasive, point-of-care instrument to assist in the early diagnosis of melanoma, raised approximately $11.8 million. The money was generated by a stock sale to fund continued development and precommercialization activities. The company reports that MelaFind has been studied on approximately 6000 skin lesions from approximately 4500 patients at more than 30 clinics. In these tests, MelaFind missed fewer melanomas and produced fewer false positives than the skin-cancer specialists who participated in the studies. MelaFind combines advanced imaging technology with specialized algorithms.


Innolume (Dortmund, Germany) says it has secured a Series C round of financing for €8.6 million (US$12.6 million). The funds will help further two major initiatives, including enhanced production and marketing of its quantum-dot laser products for medical and other applications. Juergen Kurb, CEO of Innolume, said, “this funding will also enable Innolume to rapidly introduce to the market novel quantum-dot-based devices aimed at specific high-value medical applications.” Innolume provides quantum-dot laser diodes and modules covering the 1000 to 1320 nm spectrum.

Michelson Diagnostics

Michelson Diagnostics (MDL; London, U.K.) credits successful results and growing sales with attracting an additional €600,000 (US$1.1 million) from investors. The funds will help MDL complete development of its hand-held in vivo optical coherence tomography (OCT) probe. The device is designed for cancer diagnosis and treatment, and uses OCT to provide real-time images of sub-surface tissue at near-cellular resolution without tissue removal.

“We are very excited about the breakthrough in image quality that this system offers,” said Mr. Colin Hopper, senior maxillofacial surgeon at University College Hospital, London. “OCT could revolutionize the surveillance of precancers in the mouth and eliminate the waiting time for biopsy results. It should also minimize surgery through improved disease mapping. This will provide cost effective treatments with improved cure rates.”

About the Author

Barbara Gefvert | Editor-in-Chief, BioOptics World (2008-2020)

Barbara G. Gefvert has been a science and technology editor and writer since 1987, and served as editor in chief on multiple publications, including Sensors magazine for nearly a decade.

Sponsored Recommendations

Request a free Micro 3D Printed sample part

April 11, 2024
The best way to understand the part quality we can achieve is by seeing it first-hand. Request a free 3D printed high-precision sample part.

How to Tune Servo Systems: The Basics

April 10, 2024
Learn how to tune a servo system using frequency-based tools to meet system specifications by watching our webinar!

Motion Scan and Data Collection Methods for Electro-Optic System Testing

April 10, 2024
Learn how different scanning patterns and approaches can be used in measuring an electro-optic sensor performance, by reading our whitepaper here!

How Precision Motion Systems are Shaping the Future of Semiconductor Manufacturing

March 28, 2024
This article highlights the pivotal role precision motion systems play in supporting the latest semiconductor manufacturing trends.

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!